The Clinical Research Department at BC Cancer was established to be the central point of contact for investigators wanting to undertake clinical research at BC Cancer. 

The goals of the department are to improve the quality and productivity of clinical research at BC Cancer while encouraging a culture of innovation, responsibility and accountability.  The Clinical Research Department is committed to ensuring BC Cancer clinical research is operationally efficient and of high quality.  We will achieve this by standardizing practices across the province, providing comprehensive education programs and quality and metrics reporting and administrative support for clinician-investigators.

From Research to Treatment

Many of the treatments we have in Canada today are available thanks to people who volunteer to take part in a clinical trial​.  
Find out more about clinical trials

News & Events

Improving health outcomes in breast radiotherapy: A universal solution for every body

For patients undergoing breast radiotherapy to treat their cancer, receiving a high-quality standard of care is important – particularly given they receive treatment over several sessions. 

However, this consistency can be challenging to maintain as each patient’s body is different. Positioning the breast accurately is key to ensuring the radiation targets the right area, yet variations in body shape and size can make this difficult. 

Small centre, big Impact: Prince George clinicians co-author three Lancet Oncology papers

Investigators from BC Cancer – Prince George (Centre for the North) are co-authors on three international collaborative publications featured in the same issue of The Lancet Oncology. These papers reflect the centre’s engagement in global research collaborations that shape how cancer care is studied, reported, and delivered.

 

Blood test expands access to FGFR-targeted therapy for metastatic urothelial cancer

Researchers at BC Cancer Research Institute, led by Dr. Bernie Eigl, director of the Provincial Clinical Trials Office, and Dr. Alex Wyatt, senior scientist and scientific director of the Cancer Genetics and Genomics Laboratory, examined whether a blood test that analyzes cancer-derived DNA found in the blood, called circulating tumour DNA (ctDNA), could help identify more patients with metastatic urothelial carcinoma – an aggressive form of bladder cancer – who are eligible for FGFR-targeted therapy.

Recent Publications

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).

Eur Urol, 2025
Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A.
Learn More
Back to top